Physician profile

Latoya C Murphy

Psychiatric/Mental Health (Nurse Practitioner) · Avondale, AZ

NPI 1275195653

$1,167.58

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$482.51

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corium, LLC $384.50 2022-2024 Azstarys
Janssen Pharmaceuticals, INC $268.45 2022-2023 Spravato
Otsuka America Pharmaceutical, INC. $221.36 2022-2023 Rexulti, Abilify Mycite
Ironshore Pharmaceuticals INC. $167.44 2022-2023 Jornay Pm
Neurocrine Biosciences, INC. $52.05 2022
Abbvie INC. $51.55 2023
Lundbeck LLC $22.23 2023 Rexulti

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Latoya C Murphy

$1,167.58

in general payments reported 2019-2025

Years
2022-2024
Top company
Corium, LLC

https://glasscript.com/doctor/10876591/latoya-c-murphy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.